“Growing Focus on Oral Supportive Care Therapies”
- A prominent trend in the cancer supportive care products market is the shift toward oral formulations for managing side effects such as nausea, anemia, and neutropenia, driven by patient convenience and adherence benefits
- Oral supportive care drugs are being increasingly favored over intravenous formulations due to lower hospitalization needs, reduced healthcare costs, and enhanced patient quality of life
- This trend aligns with the industry’s broader move toward outpatient care and home-based cancer treatment protocols
- For instance, in 2023, Amgen expanded access to its oral antiemetic portfolio to support outpatient chemotherapy centers across the U.S.
- The growing preference for oral supportive care options is improving patient compliance, expanding market reach, and reshaping cancer treatment delivery models
